about
Cloning of the pig PEPT2 (pPEPT2) and characterization of the effects of epidermal growth factor (EGF) on pPEPT2-mediated peptide uptake in the renal porcine cell line LLC-PK1In-depth evaluation of Gly-Sar transport parameters as a function of culture time in the Caco-2 cell model.SGLT1-mediated Transport in Caco-2 Cells Is Highly Dependent on Cell Bank Origin.Discovery of ligands for the human intestinal Di-/Tripeptide transporter (hPEPT1) using a QSAR-assisted virtual screening strategy.Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and patho-physiological conditions.Delivery aspects of small peptides and substrates for peptide transporters.Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions.Interaction of GABA-mimetics with the taurine transporter (TauT, Slc6a6) in hyperosmotic treated Caco-2, LLC-PK1 and rat renal SKPT cells.PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats.The absorptive flux of the anti-epileptic drug substance vigabatrin is carrier-mediated across Caco-2 cell monolayers.Basolateral glycylsarcosine (Gly-Sar) transport in Caco-2 cell monolayers is pH dependent.Calu-3 cells grown under AIC and LCC conditions: implications for dipeptide uptake and transepithelial transport of substances.Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen.In Vitro Membrane Permeation Studies and in Vivo Antinociception of Glycosylated Dmt(1)-DALDA Analogues.A quantitative structure-activity relationship for translocation of tripeptides via the human proton-coupled peptide transporter, hPEPT1 (SLC15A1)5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination.The tandem chain extension aldol reaction used for synthesis of ketomethylene tripeptidomimetics targeting hPEPT1Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1).Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity.Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations.Epidermal growth factor decreases PEPT2 transport capacity and expression in the rat kidney proximal tubule cell line SKPT0193 cl.2.Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line.Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line.Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line.Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro.Intestinal absorption of the antiepileptic drug substance vigabatrin is altered by infant formula in vitro and in vivo.Oral and intravenous pharmacokinetics of taurine in sprague-dawley rats: the influence of dose and the possible involvement of the proton-coupled amino acid transporter, PAT1, in oral taurine absorption.Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan.Identification and Characterization of a Novel Nontranslated Sequence Variant of the Human Intestinal Di-/Tripeptide Transporter, hPEPT1.Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs.An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media.Model prodrugs designed for the intestinal peptide transporter. A synthetic approach for coupling of hydroxy-containing compounds to dipeptides.Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism.Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells.Genetic variants of the human dipeptide transporter PEPT1.Carbonic anhydrase inhibitors: transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters.Glutamate Transporters in the Blood-Brain Barrier.Characterization of the L-glutamate clearance pathways across the blood-brain barrier and the effect of astrocytes in an in vitro blood-brain barrier model.In vitro evidence for the brain glutamate efflux hypothesis: brain endothelial cells cocultured with astrocytes display a polarized brain-to-blood transport of glutamate.
P50
Q28269836-C3867DEC-17B5-4DDF-8B5E-4803334D7FE0Q33196489-9E5EC9B4-0311-4166-A34D-996075553B87Q33459228-AC413E60-87E4-49E6-90C3-FF530C1B8D46Q33474995-B279D911-18F3-48AD-BC7E-5298900DCE2AQ35158253-5B118D37-B751-4F1B-8279-A15C82B5DD71Q36134559-280C3EA1-6653-48F5-8485-1195A8B4F49DQ38261962-EF63909B-6446-4E49-A9C9-6A6B57CD7537Q38814736-4B59A884-3B22-4050-8614-5B0B65E3CD0FQ39063741-6375D745-C473-42C3-8B6E-253EFB9DC868Q39099792-1ED56FBF-1C89-4901-9F9A-6A75D05C6ACFQ39143689-438BF8E9-ACEA-459A-AC9A-42AF197FF1A7Q39613423-4F38D918-BB77-4508-8252-949E228F20F7Q39665168-4E6A8FCA-A927-4A04-82B7-44C70D2FF83DQ39681968-8CB8EAD4-14D5-4032-AECC-21079F27B880Q39706601-3DC1DE4C-4E75-4C17-97AF-4FFB84561EA2Q39777134-77C63AA7-370C-4EEC-B4D6-F53A863AA250Q39782583-EFD6F410-3751-4B4E-91EB-5C031FD71C5DQ39884569-F5578DB0-C1F1-40D2-800E-D2DF1C6CB34EQ39994950-6DFC54D0-8DF5-4AAA-9B84-B1FCD2ADD564Q40592833-EBBAC7FB-B108-43EF-AF94-DCD17DEF2341Q40626181-07CEA648-3BB0-4EEF-BCC4-A4ADAE8F11B6Q40693986-CAA5A8B4-6A1F-4DE9-BAD2-24F0C68EE325Q40782816-58CEF090-3138-4918-8378-771092012555Q40799214-DDFEB21E-7CEE-436D-9D3F-15AC268332F6Q41882651-F9153374-2F78-4F46-8CF8-8F0B995F1F32Q42080942-71FAFFEA-6DBD-44B0-B94E-9FEC77DD7B52Q42378115-34C3B4B5-4363-4B54-A03A-540680FD2490Q42589049-603D8431-D2D1-4E4C-A945-841F14EA10C2Q42747654-C63E475A-1B91-4350-910A-1390A059D001Q42781435-810AB789-AA7B-47D4-96B0-BB0F17F8B2C2Q42846693-F1E54910-8E0A-4446-941C-6A2C1623A413Q43597565-D1AF97FD-8710-4272-B6D9-2337B8640736Q43678463-8786A863-B4AC-4491-80A0-87ED4D68C84CQ44277341-A3C9859D-6699-439A-8E03-FB92BF972CB3Q46487664-67DF8673-B9F6-4D71-ADD6-62279EAF4246Q46781695-05C56014-1545-4856-BD3B-AE943C73377FQ46830591-DFD5B4C4-B4B7-4B17-8B2A-C44AF5FA3BDEQ47923107-04E56B02-F252-4EBF-BA92-5E555A41505CQ48329959-40E7BB69-EB4D-4A7F-8B7B-C6FFF29F7052Q48627645-7977DA08-4FD9-4EA6-8477-A2D01ABCCADE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carsten Uhd Nielsen
@ast
Carsten Uhd Nielsen
@en
Carsten Uhd Nielsen
@es
Carsten Uhd Nielsen
@nl
Carsten Uhd Nielsen
@sl
type
label
Carsten Uhd Nielsen
@ast
Carsten Uhd Nielsen
@en
Carsten Uhd Nielsen
@es
Carsten Uhd Nielsen
@nl
Carsten Uhd Nielsen
@sl
altLabel
Carsten Uhd Nielsen
@en
prefLabel
Carsten Uhd Nielsen
@ast
Carsten Uhd Nielsen
@en
Carsten Uhd Nielsen
@es
Carsten Uhd Nielsen
@nl
Carsten Uhd Nielsen
@sl
P106
P1153
7201429174
P21
P31
P496
0000-0001-5776-6865